Armstrong Teasdale attorneys have experience representing pharmaceutical and biotechnology clients in complex patent litigation, including matters involving Abbreviated New Drug Application (ANDA) litigation and the Hatch-Waxman Act. Historically, these matters have been most frequently brought in courts in Delaware and New Jersey, where attorneys in our IP Litigation practice are intimately familiar with the courts and key players. These attorneys also have experience advising clients on parallel strategy before the Patent Trial and Appeal Board (PTAB) and in post grant proceedings.

We work closely with drug manufacturers in handling various validity and infringement claims, including Paragraph IV Drug Product Applications, and have served as local counsel, as well as lead counsel, at trial and on appeal, advising pharmaceutical clients throughout the life cycle of a patent.

Our active Intellectual Property (IP) practitioners, who have been recognized among the IAM Patent 1000, Benchmark Litigation and IP Stars, guide clients in all aspects of the acquisition, licensing, application, protection and enforcement of their IP rights, including developing extensive global patent portfolios. As such, they understand the various avenues available to pharmaceutical litigants and know that ANDA litigation stands to have broader implications for the health care and life sciences sector. 

Our attorneys also have regulatory compliance experience working alongside various state and federal agencies and regulatory bodies, including the U.S. Food and Drug Administration (FDA), World Health Organization (WHO) and World Intellectual Property Organization (WIPO).